{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Number of Participants with Dose Limiting Toxicity of MLN9708 (lxazomib) according to CTCAE version 4.03","groups":[{"description":"Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28","id":"OG000","title":"Dose Levels 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received treatment in the phase I portion of the study","reportingStatus":"POSTED","timeFrame":"at 28 days from start of treatment","title":"Number of Participants With Dose Limiting Toxicity According to CTCAE Version 4.03","type":"PRIMARY","unitOfMeasure":"Participants"}